Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solsence is a topical broad-spectrum sunscreen formulation developed and marketed by Ernst Pharmacia. It is designed to provide high-level protection against the harmful effects of ultraviolet (UV) radiation, specifically targeting both UVA and UVB rays. The product typically contains a synergistic combination of chemical UV filters, such as octyl methoxycinnamate (ethylhexyl methoxycinnamate), avobenzone (butyl methoxydibenzoylmethane), and oxybenzone (benzophenone-3), alongside physical blockers like zinc oxide. This multi-component approach allows the formulation to absorb, reflect, and scatter UV photons, thereby preventing acute conditions like sunburn and long-term damage such as photoaging and skin carcinogenesis. Solsence is primarily marketed as a gel or lotion for dermatological use and is often positioned as an SPF 50+ protective agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Solsence.